

## **CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform**

Munich and Freiburg, Germany, May 7, 2008 – CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures.

Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grade protein kinase portfolio, optimized and quality-controlled for successful crystallization. In addition, the two companies will work closely together to provide new crystal-grade protein or crystal structures, tailored to meet customers' needs.

Recombinant protein kinases, optimized for crystallization, will be produced and exclusively marketed by ProQinase, while CRELUX will continue to provide customers with crystallization and x-ray crystallography services. CRELUX will support ProQinase by performing crystallization quality control for each crystal grade protein batch. At the same time, ProQinase will grant CRELUX privileged direct access to kinase crystal-grade protein.

*"This new joint crystal-grade kinase platform offers tremendous advantages: It enables us to continue to focus on our core expertise – complex structure solution – while leveraging the expertise of ProQinase to significantly strengthen our capacities in protein expression," commented Dr. Michael Schäffer, CEO of CRELUX.*

*"The combination of CRELUX's expertise in protein crystallography and ProQinase's know-how in kinase cloning and expression makes the two companies the partners of choice for all customers interested in kinase crystallography," noted Dr. Christoph Schächtele, CEO of ProQinase.*





CRELUX has used its state-of-the-art structural biology platform to solve more than 250 crystal and co-crystal structures for pharma and biotech companies. This platform encompasses all steps – from target cloning and expression all the way to high-throughput protein crystallization and in-house x-ray crystallography.

ProQinase, as part of its integrated protein kinase technology platform, offers more than 150 recombinant human protein kinases – all produced in-house – and provides all types of *in vitro* testing services, with more than 220 protein kinases.

- END-

For immediate release

For further information please contact:

Dr. Michael Schäffer – CEO CRELUX GmbH – Tel: +49-89-700760-170

Dr. Alexander Baumann – ProQinase GmbH – Tel.: +49-761-206-1780

#### **Notes to editors**

**CRELUX GmbH** ([www.crelux.com](http://www.crelux.com)) provides fast and affordable access to co-crystal structures for biotech and pharma companies worldwide. Three dimensional structures of target-compound complexes are unique sources of information during the rational drug discovery process. Straightforward availability of structural data at an early stage of the drug development process significantly enhances productivity and success rates during hit selection, lead generation, and lead optimization. CRELUX has streamlined the processes of structure generation and solved hundreds of co-crystal structures using an integrated technology platform. In addition to customer designed projects crystallization conditions of numerous relevant therapeutic targets are available within the Off-The-Shelf Program of CRELUX. Off-The-Shelf target structures are delivered at a fixed price and short turn around times, facilitating affordable access to structural information.

**ProQinase GmbH** ([www.proqinase.com](http://www.proqinase.com)) provides an Integrated Protein Kinase Technology (iProKiTe<sup>®</sup>) Platform for preclinical drug development of protein kinase inhibitors. More than 150 highly active recombinant kinases are offered for sale and more than 220 kinases are available for *in vitro* testing services (HTS and selectivity profiling etc.). Cellular and *in vivo* test systems including orthotopic tumor models allow further testing of lead compounds. A Clinical biomarker analysis service supports the evaluation of clinical trials.